Article: Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent.

The World's First Peripheral Drug-Eluting Stent Now Available in Europe

VANCOUVER, Aug. 11 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, reported CE Mark approval and limited commercial launch of the Zilver(R) PTX(R) Drug-Eluting Peripheral Stent in Europe. This approval represents a global landmark in bringing drug-eluting stent (DES) technology to people suffering from peripheral artery disease (PAD), a chronic disease affecting tens of millions of patients worldwide that is a leading cause of leg amputation and shortened lifespan.

"The awarding of the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!